First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
A phase 1/2 trial of AZD9793 in hepatocellular carcinoma, run by AstraZeneca, now recruiting.
Overview
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours is a phase 1/2 interventional study registered as NCT06795022 by AstraZeneca, with 304 participants planned, started 2025-03-27 and due to reach its primary completion in 2027-06-30. Interventions recorded: AZD9793 Intravenous (IV) monotherapy and AZD9793 Subcutaneous (SC) monotherapy.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Shares AstraZeneca, Hepatocellular carcinoma and the tag pipeline.
- TrialA Study of PTX-9908 Injection for Non-resectable HCC with TACE
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialGPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialTo Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialA Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Shares Hepatocellular carcinoma and the tag pipeline.